Biotech ETFs are heading into a potentially pivotal week after missing last week’s broader market rally, with two closely watched FDA decisions, Alzheimer’s research updates and obesity-drug developments offering fresh catalysts for the sector.
The SPDR S&P Biotech ETF (NYSE:XBI) fell 1.09% last week, while the iShares Biotechnology ETF (NASDAQ:IBB) slipped 0.53%. The weakness contrasted with a 2.19% gain for the Health Care Select Sector SPDR Fund (NYSE:XLV), a 2.59% advance for the SPDR S&P 500 ETF Trust (NYSE:SPY) and a 3.63% rally in the Invesco QQQ Trust (NASDAQ:QQQ).
The divergence highlights how biotech stocks have struggled to participate in the broader risk-on move, even as health care shares advanced.
Two FDA Decisions Could Test Biotech Sentiment
The biggest near-term catalysts arrive Nov. 22, when the FDA is expected to decide on treatments from Capricor Therapeutics Inc (NASDAQ:CAPR) and Savara Inc (NASDAQ:SVRA).
Capricor is seeking approval for deramiocel, a treatment for Duchenne muscular dystrophy. The company reported that patients in its Hope-3 extension study experienced a 76% slowing in upper-limb decline after switching from placebo to treatment.
Savara, meanwhile, is awaiting a decision on molgramostim for autoimmune pulmonary alveolar proteinosis, a rare lung disease. The inhaled treatment has priority review status, although the FDA extended its review to assess additional information. The company said the correspondence identified no safety, efficacy or manufacturing concerns.
Both decisions could influence investor appetite for smaller biotechnology companies, particularly those whose valuations depend heavily on clinical and regulatory milestones.
Alzheimer’s and Obesity Drugs Add More Catalysts
The Clinical Trials on Alzheimer’s Disease conference this week brings further attention to the sector. Eisai, which developed lecanemab with Biogen Inc (NASDAQ:BIIB), is presenting five-year findings for the drug, while Roche is sharing early data on trontinemab and updates on its experimental Alzheimer’s pipeline.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) will also detail Phase 2 results for remlifanserin, targeting hallucinations and delusions associated with Alzheimer’s disease.
Meanwhile, Eli Lilly and Co.’s (NYSE:LLY) latest obesity-drug data and Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP) early-stage results for its experimental weight-loss pill offer additional developments for health care investors.
However, Summit Therapeutics’ (NASDAQ:SMMT) FDA setback over its lung-cancer treatment is a reminder that encouraging clinical data do not guarantee regulatory approval.
For XBI and IBB investors, the coming days could provide a crucial test of whether a packed pipeline of clinical and regulatory catalysts can revive interest in a sector that has so far missed Wall Street’s rally.
XBI Price Action: The SPDR S&P Biotech ETF was down 0.35% at $150.03 in premarket trading Monday, according to Benzinga Pro data.
Photo: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.




